Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: MMender who wrote (29)	1/25/1999 2:56:00 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 360

Mike; Sorry but I still cannot get VCALL, so I cannot comment on what you heard there. I even installed the most recent RealPlayer and tested it. It works fine as it did before, but for whatever reason I am not able to get VCALL running. "ADODB.field error" whatever that might mean. I have heard Brenner before, but also wanted to hear OSIP and DIGE. Hopefully Steve Push can comment on GLGC's science strategy. It is my understanding that GLGC with its tissue bank is following the progression of disease as that progression is read in the genetic code. By understanding how the genetic code changes during a disease is different from mutations that are read in one's genome such as the well known cancer genes. But even if you have a gene such as BRCA1, you are not born with cancer and in fact might never get it. So what happens and why are some patients helped with some medicines and others are not? Isn't this the science of Pharmacogenomics? Instead of blindly or almost blindly looking for drugs that will effect the outcome of disease it is my belief that GLGC expects to be able to turn this around and by understanding what takes place in the individual may be able to target those changes. I have over simplified for sure and you are correct when you say that "the cascade of cellular events is so vast..." and yet our abilities with the aid of computers surely is starting to put these complicated interactions into an understandable sequence which is forever changing medicine. Companies are moving beyond sequencing of the genome to mapping protein interactions and as this becomes understood surely targeting compounds will not start at the bottom it will start at "the top". In any case these are really exciting concepts and science and as it all unfolds I think there will be some real winners here. I hope that Steve has started checking in here so that he can correct where I am wrong. steve